Demographics
We screened a total of 486 patients from March 2022 to Jun 2022, of which 329 patients did not meet inclusion criteria and 57 patients declined to participate in our study. We finally enrolled 100 patients, 50 patients were assigned to fluvoxamine and 50 to Placebo. At 12 weeks of follow-up, 85 patients were eligible for PCS evaluation (42 in fluvoxamine and 43 in Placebo), 9 discontinued medication and we were unable to contact 6 patients (Fig. Patients enrollment and follow-up flowchartPatients had a mean age of 38.5 ± 14.1 (39.8 ± 14 in fluvoxamine and 37.2 ± 14.3 in placebo) and 41 of the patients were women (20 in fluvoxamine and 22 in Placebo). Most of the patients received AstraZeneca (23, 13 in fluvoxamine and 10 in placebo) and Sinopharm (59, 28 in fluvoxamine and 31 in placebo) COVID-19 vaccine. No significant difference was observed between fluvoxamine and placebo groups in terms of baseline characteristics (Table Baseline characteristics of patients